Conspiracy theorist reprimanded by coroner at inquest into daughter's death
Paloma Shemirani, 23, died at Royal Sussex County Hospital in Brighton on July 24, 2024 after declining the treatment for non-Hodgkin lymphoma.
She grew up in Uckfield and attended Roedean School for sixth form.
Her mother, Kay 'Kate' Shemirani, rose to prominence on social media while sharing Covid-19 conspiracy theories, the inquest at Oakwood House in Maidstone, Kent, heard previously.
In written statements submitted to the family division of the High Court in Spring 2024, Paloma said she declined chemotherapy partly because of her 'background in natural healing', the inquest heard on Monday.
The proceedings, which involved the Maidstone and Tunbridge Wells NHS Trust, were on the appropriateness of her care and Paloma said she was 'delighted' with her alternative treatment and 'sure' she would 'make a full recovery' if left to continue it, the inquest was told.
She also claimed her human rights had been violated by NHS practitioners in the statements, which were read by lawyer Alison Hewitt.
Ms Shemirani, who attended the inquest via video link, wept and held pictures of Paloma to the camera as they were read.
It said: 'I am far from being a vulnerable young adult. Apart from becoming independent after I moved to Cambridge for university, I have practised the same principles that I grew up with.
'I have always been extremely health conscious: sticking to all-organic produce, I prepare all my own meals and I absolutely do not drink or cook with tap water.
'I have never taken drugs, despite pressure to, and I rarely drink alcohol.
'If I became ill, I've always turned to my mum first for advice as she is a trained nurse and qualified nutritionist.
'Practically fanatical about my health, my close friends know me as a staunch advocate for all proven natural healing'.
Gabriel Shemirani, outside Oakwood House in Maidstone, Kent, for the inquest into the death of his sister (Image: PA) She also described her mother as 'an extremely forceful advocate for natural health' who is 'misquoted' by people claiming 'those natural solutions are conspiratorial'.
Ms Shemirani was struck off as a nurse in 2021, with a Nursing and Midwifery Council (NMC) committee finding that she had spread Covid-19 misinformation that 'put the public at a significant risk of harm', the inquest heard previously.
Another statement in Paloma's name added 'my friends know me as a staunch advocate of the Gerson therapy' and she stated that she is 'anti-vax'.
She said she had been using Gerson therapy as one mode of treatment on the advice of her mother's ex-fiancé, Doctor Patrick Villers, and that at 15 years old she spent three weeks in his camp in Mexico where it was practised.
Gerson therapy involves a strict organic vegetarian diet and enemas and has been used in cancer treatment, though Cancer Research UK says that there is no scientific evidence it can be used as a treatment for cancer.
Her GP was also monitoring her blood and progress, she said.
The former Cambridge student went on to deny having the disease and said 'I was not diagnosed with non-Hodgkin's lymphoma… I have never had a shadow on my lung, this is absurd fantasy, no proof'.
She described the diagnosis as 'suspected and unconfirmed', and said a 'differential diagnosis' only meant cancer could not be ruled out.
Paloma understood that she had a one in five chance of surviving the commonplace R-CHOP treatment that was offered, and feared it would likely make her infertile, the inquest heard.
'I do not want to undergo such a harsh treatment that could even kill me when there is a possibility this is not cancer', she said.
The High Court statement alleged multiple violations of human rights in her care, the inquest heard, including Articles 3, 6 and 8 and possibly Articles 1, 5 and 12.
'I am so shocked, as are others assisting me, especially my mother, that this could take place today', the statement said.
'These were put in place forever to prevent what Dr Mengele did in the Second World War. How could this happen today?', it continued.
Notorious Nazi doctor Josef Mengele performed experiments on his victims in Auschwitz.
The patient said symptoms she presented in hospital with – including a swollen face, excruciating chest pain and being unable to move her arm – had subsided.
Coroner Catherine Wood reprimanded Ms Shemirani multiple times during proceedings.
Ms Shemirani cross-examined Dr Amit Goel, a consultant histopathologist at Maidstone Hospital who carried out a biopsy.
She repeatedly put to him that insufficient tissue was taken to carry out a FISH test that could rule out other diseases and alter Paloma's treatment plan.
The doctor denied that this would have influenced Paloma's care multiple times, and the coroner told Ms Shemirani the inquest is trying to look at 'how Paloma came about her death' but 'you are apparently trying to get information which is incorrect, factually incorrect, in the statements you are making'.
'I think your questions are just designed to take up time and delay matters by the way you're asking them repeatedly,' she added.
The mother accused participants of mis-pronouncing her name, which eventually led Ms Wood to say: 'I am going to rise, for Ms Shemirani to reflect on her behaviour in court, this is unacceptable.
'Let's have a pause for tempers to die down because you are clearly becoming over-fixated on a detail.'
At the opening of the hearing Ms Shemirani made an application for a lawyer to recuse herself.
The coroner rejected the application and said had seen the 'hundreds of emails that have been sent in' and that 'you have requested that everybody recuse themselves at various times', including the coroner herself.
The inquest continues.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
Hinge Health Reports Second Quarter 2025 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the second quarter ended June 30, 2025. "In Q2 we delivered year-over-year revenue growth of 55% and a strong free cash flow margin, underlining the market's embrace of our AI-powered platform," said Daniel Perez, Co-Founder and CEO, Hinge Health. "The journey of automating healthcare delivery will be challenging, but we're excited about our momentum and are moving with haste to capture this opportunity." Second Quarter 2025 Financial Highlights: Revenue increased 55% year-over-year to $139.1 million compared to revenue of $89.8 million in Q2 2024. GAAP gross margin was 70% compared to 74% in Q2 2024. Non-GAAP gross margin was 83% compared to 77% in Q2 2024. GAAP loss from operations was $580.7 million, which included $591.0 million in stock-based compensation expense, compared to GAAP loss from operations of $17.6 million in Q2 2024. Non-GAAP income from operations was $26.1 million compared to non-GAAP loss from operations of $14.4 million in Q2 2024. Net cash provided by operating activities was $20.2 million compared to a net cash provided by operating activities of $14.9 million during Q2 2024. Free cash flow was $32.6 million, which included an adjustment of $14.2 million for employer taxes related to stock-based compensation at IPO, compared to free cash flow of $14.0 million during Q2 2024. Cash, cash equivalents, marketable securities and restricted cash were $415.1 million as of June 30, 2025. Key Metrics as of June 30, 2025: LTM calculated billings of $568.4 million compared to $367.8 million for Q2 2024, an increase of 55%. Number of clients increased 32% to 2,359 clients compared to 1,785 clients in Q2 2024. Financial Outlook: We are providing the following guidance for our third quarter and full year 2025: Q3 2025: We expect our revenue to be between $141 million and $143 million, reflecting year-over-year growth of 41% at the midpoint. We expect our non-GAAP income from operations to be between $17 million and $21 million, compared to non-GAAP loss from operations of $3.7 million in Q3 2024. Fiscal Year 2025: We expect our revenue to be between $548 million and $552 million, reflecting year- over-year growth of 41% at the midpoint. We expect our non-GAAP income from operations to be between $77 million and $83 million, compared to non-GAAP loss from operations of $26.1 million in 2024. Statement Regarding Use of Non-GAAP Financial Measures This press release uses non-GAAP financial measures, which are not calculated in accordance with generally accepted accounting principles of the United States (GAAP). For more information about these non-GAAP financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP, please see the "Non-GAAP Financial Measures" section below. Moreover, we have not reconciled our non-GAAP income (loss) from operations guidance to GAAP income (loss) from operations because we do not and are not able to provide guidance for GAAP income (loss) from operations due to the uncertainty and potential variability of stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets and adjustments, such as the excess inventory and transition charges, restructuring and other expense and acquisition related expense, which are reconciling items between non-GAAP and GAAP income (loss) from operations. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measures. However, such items could have a significant impact on our future GAAP income (loss) from operations. Hinge Health Earnings Webcast We will host a conference call and webcast for investors on August 5, 2025 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss our financial results, business highlights and financial outlook. The live webcast of the conference call can be accessed by registering online at Following completion of the events, a webcast replay will also be available at for 12 months. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting with musculoskeletal conditions. Leveraging an AI-powered care model, a wearable device, and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain, improving member outcomes and experiences and reducing costs for clients. The Company is headquartered in San Francisco, California. Available Information Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our Company through a variety of means, including filings with the U.S. Securities and Exchange Commission ("SEC"), the investor relations page on our website ( press releases, public conference calls, and webcasts in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our obligations under Regulation FD. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' or 'will,' or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our outlook and guidance for the third quarter of 2025 and guidance for full year 2025 and our assumptions underlying such guidance; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including those more fully described under the caption 'Risk Factors' in our Prospectus dated May 21, 2025, filed with the SEC on May 22, 2025, and elsewhere in documents that we file with the SEC, including our Quarterly Report on Form 10-Q for the second quarter ended June 30, 2025, which will be filed with the SEC on or around August 11, 2025. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law. HINGE HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS unaudited (in thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue $ 139,098 $ 89,825 $ 262,923 $ 172,533 Cost of revenue 41,335 23,208 64,927 47,976 Gross profit 97,763 66,617 197,996 124,557 Operating expenses: Research and development 279,962 24,920 303,462 54,683 Sales and marketing 147,228 44,894 193,944 87,037 General and administrative 251,244 14,354 268,125 31,812 Total operating expenses 678,434 84,168 765,531 173,532 Loss from operations (580,671 ) (17,551 ) (567,535 ) (48,975 ) Other income: Other income, net 4,694 4,986 9,695 10,104 Net loss before income taxes (575,977 ) (12,565 ) (557,840 ) (38,871 ) Provision (benefit) for income taxes (326 ) 361 672 519 Net loss $ (575,651 ) $ (12,926 ) $ (558,512 ) $ (39,390 ) Adjustment to reflect deemed contribution from Series D and Series E redeemable convertible preferred stock extinguishment — — 104,174 — Net loss per share attributable to common stockholders, basic and diluted $ (13.10 ) $ (0.96 ) $ (15.05 ) $ (2.93 ) Expand HINGE HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS unaudited (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating activities Net loss $ (575,651 ) $ (12,926 ) $ (558,512 ) $ (39,390 ) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation and amortization 1,343 1,554 2,646 3,168 Stock-based compensation 590,983 306 590,990 610 Amortization of deferred commissions 10,680 7,147 19,870 13,411 Accretion of discounts and amortization of premiums on marketable securities, net 277 11 326 217 Excess and obsolete inventory charge — 1,309 — 1,812 Non-cash operating lease expense 843 925 1,688 1,833 Provision for credit losses 1,894 1,570 2,780 2,487 Deferred income taxes 90 — 96 — Other 2 (6 ) (2 ) (3 ) Changes in operating assets and liabilities: Accounts receivable (25,304 ) (6,069 ) (59,584 ) (23,281 ) Deferred commissions (17,020 ) (11,165 ) (27,650 ) (18,171 ) Inventory (1,202 ) (402 ) (3,114 ) 1,137 Prepaid expenses and other current assets (14,743 ) 4,163 (6,609 ) 1,295 Other assets (211 ) (283 ) (485 ) 239 Accounts payable and accrued liabilities (8,713 ) (15,574 ) 6,997 (7,661 ) Operating lease liabilities (851 ) (1,195 ) (1,792 ) (2,372 ) Deferred revenue 57,810 45,558 57,505 46,934 Net cash provided by (used in) operating activities 20,227 14,923 25,150 (17,735 ) Investing activities: Purchase of property and equipment (197 ) (437 ) (248 ) (567 ) Capitalized internal use software (1,630 ) (497 ) (2,336 ) (1,316 ) Purchases of marketable securities (85,110 ) (84,453 ) (175,282 ) (160,768 ) Maturities of marketable securities 90,958 88,056 164,556 181,550 Acquisition of a business — — (4,000 ) — Net cash provided by (used in) investing activities 4,021 2,669 (17,310 ) 18,899 Financing activities: Proceeds from exercise of stock options 159 218 256 277 Proceeds from issuance of common stock in initial public offering, net of issuance costs 255,675 — 255,675 — Tax withholdings on settlement of restricted stock units and performance-based restricted stock units (272,258 ) — (272,258 ) — Payment on Repurchase Agreement with Coatue (50,000 ) — (50,000 ) — Proceeds from repayment of non-recourse loans to employees — — 4,934 — Payments for deferred offering costs (9,134 ) (125 ) (10,061 ) (125 ) Net cash provided by (used in) financing activities (75,558 ) 93 (71,454 ) 152 Net increase (decrease) in cash (51,310 ) 17,685 (63,614 ) 1,316 Cash, cash equivalents and restricted cash, beginning of period 290,282 221,105 302,586 237,474 Cash, cash equivalents and restricted cash, end of period $ 238,972 $ 238,790 $ 238,972 $ 238,790 Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: Cash and cash equivalents $ 237,170 $ 236,628 $ 237,170 $ 236,628 Restricted cash 1,802 2,162 1,802 2,162 Total cash, cash equivalents and restricted cash $ 238,972 $ 238,790 $ 238,972 $ 238,790 Expand Glossary of Terms LTM Calculated Billings: We believe calculated billings on a last 12-months basis helps investors better understand our performance for a particular period given the seasonality in our model due to quarterly fluctuations based on the timing of new client launches and number of intra-year launches. We anticipate that this seasonality will continue and therefore focus on LTM calculated billings. Our revenue generally does not reflect this seasonality and these quarterly fluctuations given that we recognize revenue ratably over the term that members have access to our platform. LTM calculated billings are defined as total revenue, plus the change in deferred revenue, less the change in contract assets for a given 12-month period. Number of Clients: We view this number as an important metric to assess the performance of our business as an increased number of clients drives growth, increases brand awareness, and helps provide scale to our business. Clients are defined as businesses or organizations, which we call entities, that have at least one active agreement with us at the end of a particular period. Entities that procure our platform through our partners are counted as individual clients. We do not count our partners as clients, unless they also separately have at least one active client agreement with us. When a partner has an agreement with us for their fully-insured population, that partner is deemed to be one client, despite there being multiple fully-insured employers within that entity that have access to our platform. Non-GAAP Financial Measures In addition to our results prepared in accordance with GAAP, we believe the following non-GAAP financial measures, including non-GAAP gross profit and gross margin, non-GAAP income (loss) from operations and operating margin, non-GAAP operating expenses, and free cash flow and free cash flow margin included in this press release, provide users of our financial information with additional useful information in evaluating our performance and liquidity and allows them to more readily compare our results across periods without the effect of non-cash and other items as detailed below. Additionally, our management and board of directors use our non-GAAP financial measures to evaluate our performance and liquidity, identify trends and make strategic decisions. There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes. Our non-GAAP financial measures should not be considered in isolation or as alternatives to gross profit, gross margin, income (loss) from operations, net cash provided by (used in) operating activities or any other measure of financial performance calculated and presented in accordance with GAAP. Non-GAAP Gross Profit and Gross Margin We define non-GAAP gross profit as gross profit presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including excess and obsolete inventory charges related to our AI-powered motion tracking technology transition, stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets, and restructuring and other expenses. We define non-GAAP gross margin as non-GAAP gross profit divided by revenue. The principal limitation of non-GAAP gross profit and non-GAAP gross margin is that they exclude significant expenses that are required by GAAP to be recorded in our consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations. Non-GAAP Income (Loss) From Operations and Operating Margin We define non-GAAP income (loss) from operations as income (loss) from operations presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including excess and obsolete inventory charges related to our AI-powered motion tracking technology transition, stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets, restructuring and other expenses and acquisition-related expenses. We define non-GAAP operating margin as non-GAAP income (loss) from operations divided by revenue. The principal limitation of non-GAAP income (loss) from operations and non-GAAP operating margin is that they exclude significant expenses that are required by GAAP to be recorded in our consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations. Non-GAAP Operating Expenses We define non-GAAP operating expenses as operating expenses presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including stock-based compensation expense, employer payroll tax expense related to stock-based compensation, restructuring and other expenses and acquisition-related expenses. The principal limitation of non-GAAP research and development expenses, non-GAAP sales and marketing expenses and non-GAAP general and administrative expenses is that they exclude significant expenses that are required by GAAP to be recorded in our consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations. Free Cash Flow and Free Cash Flow Margin We define free cash flow as net cash provided by (used in) operating activities plus cash used for employer payroll taxes related to pre-IPO stock-based compensation less purchases of property, equipment and software (including capitalized internal-use software). We believe that free cash flow is a helpful indicator of liquidity that provides information to management and investors about the amount of cash generated or used by our operations that, after taking into account the employer payroll taxes paid as part of the vesting of shares at IPO as well as investments in property, equipment and software (including capitalized internal-use software), can be used for strategic initiatives, including investing in our business and strengthening our financial position. The principal limitation of free cash flow is that it does not represent the total increase or decrease in our cash balance for a given period. We define free cash flow margin as free cash flow divided by revenue. We adjust the following items from one or more of our non-GAAP financial measures: Excess and obsolete inventory charges. We exclude certain charges related to excess and obsolete inventory related to our AI-powered motion tracking technology transition, which was our strategic decision in the first half of 2023 to shift away from providing kits with tablets and wearable sensors. As part of this shift, we began to provide access to our platform through our app on members' personal smartphones or tablets and replaced sensors for members with our proprietary AI-powered motion tracking technology. We exclude these charges because we do not believe these expenses have a direct correlation to the operating performance of our business. Stock-based compensation expense. We exclude stock-based compensation expense, which is a non-cash expense, from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding our operating performance. Employer payroll tax expense related to stock-based compensation. We exclude expenses for employer payroll taxes related to stock-based compensation from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding operational performance. In particular, this expense is tied to the exercise, vesting or sale of underlying equity awards and the price of our common stock at the time of exercise, vesting or sale which may vary from period to period independent of the operating performance of our business. Amortization of intangible assets. We exclude amortization of intangible assets, which is a non-cash expense, from certain of our non-GAAP financial measures. Our expenses for amortization of intangible assets are inconsistent in amount and frequency because they are significantly affected by the timing, size of acquisitions and the inherent subjective nature of purchase price allocations. We exclude these amortization expenses because we do not believe these expenses have a direct correlation to the operating performance of our business. Restructuring and other expenses. We exclude certain charges that are mainly attributable to workforce reduction in order to simplify our operations and better align our resources with our priorities. We exclude these charges because we do not believe these charges have a direct correlation to the operating performance of our business. Acquisition-related expenses. We exclude certain charges that are attributable to acquiring businesses. We exclude these charges because we do not believe these charges have a direct correlation to the operating performance of our business. Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 GAAP loss from operations $ (580,671 ) $ (17,551 ) $ (567,535 ) $ (48,975 ) GAAP operating margin (417 )% (20 )% (216 )% (28 )% Excess and obsolete inventory charges (1) — 1,309 — 1,812 Stock-based compensation expense (2) 590,983 306 590,990 610 Employer payroll tax expense related to stock-based compensation 14,227 (6,253 ) 14,227 (6,253 ) Amortization of intangible assets 225 95 406 189 Restructuring and other expenses — 7,599 — 8,671 Acquisition-related expenses 1,337 100 2,968 100 Non-GAAP income (loss) from operations $ 26,101 $ (14,395 ) $ 41,056 $ (43,846 ) Non-GAAP operating margin 19 % (16 )% 16 % (25 )% Expand (1) Reflects our strategic decision in the first half of 2023 to shift away from providing kits with tablets and wearable sensors. As part of this shift, we began to provide access to our platform through our app on members' personal smartphones or tablets and replaced all sensors for members with our proprietary AI-powered motion tracking technology. (2) Stock-based compensation expense: Expand Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Cost of revenue $ 16,441 $ 37 $ 16,441 $ 72 Research and development 248,809 81 248,809 161 Sales and marketing 95,050 89 95,050 181 General and administrative 230,683 99 230,690 196 $ 590,983 $ 306 $ 590,990 $ 610 Expand HINGE HEALTH, INC. unaudited (in thousands, except for percentages) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 GAAP research and development $ 279,962 $ 24,920 $ 303,462 $ 54,683 GAAP research and development as a percentage of revenue 201 % 28 % 115 % 32 % Stock-based compensation expense (2) (248,809 ) (81 ) (248,809 ) (161 ) Employer payroll tax expense related to stock-based compensation (7,020 ) 2,852 (7,020 ) 2,852 Restructuring and other expenses — (3,428 ) — (4,394 ) Acquisition-related expenses (1,358 ) — (2,816 ) — Non-GAAP research and development $ 22,775 $ 24,263 $ 44,817 $ 52,980 Non-GAAP research and development as a percentage of revenue 16 % 27 % 17 % 31 % Expand Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 GAAP sales and marketing $ 147,228 $ 44,894 $ 193,944 $ 87,037 GAAP sales and marketing as a percentage of revenue 106 % 50 % 74 % 50 % Stock-based compensation expense (2) (95,050 ) (89 ) (95,050 ) (181 ) Employer payroll tax expense related to stock-based compensation (2,630 ) — (2,630 ) — Restructuring and other expenses — (2,004 ) — (2,053 ) Non-GAAP sales and marketing $ 49,548 $ 42,801 $ 96,264 $ 84,803 Non-GAAP sales and marketing as a percentage of revenue 36 % 48 % 37 % 49 % Expand Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 GAAP general and administrative $ 251,244 $ 14,354 $ 268,125 $ 31,812 GAAP general and administrative as a percentage of revenue 181 % 16 % 102 % 18 % Stock-based compensation expense (2) (230,683 ) (99 ) (230,690 ) (196 ) Employer payroll tax expense related to stock-based compensation (3,684 ) 3,401 (3,684 ) 3,401 Restructuring and other expenses — (1,456 ) — (1,512 ) Acquisition-related expenses 22 (100 ) (153 ) (100 ) Non-GAAP general and administrative $ 16,899 $ 16,100 $ 33,598 $ 33,405 Non-GAAP general and administrative as a percentage of revenue 12 % 18 % 13 % 19 % Expand (2) For details on stock-based compensation expense, see above. Expand Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net cash provided by (used in) operating activities $ 20,227 $ 14,923 $ 25,150 $ (17,735 ) Operating cash flow margin 15 % 17 % 10 % (10 )% Adjustment for employer taxes related to pre-IPO stock-based compensation 14,227 — 14,227 — Less purchases of property, equipment and software (including capitalized internal use software) (1,827 ) (934 ) (2,584 ) (1,883 ) Free cash flow $ 32,627 $ 13,989 $ 36,793 $ (19,618 ) Free cash flow margin 23 % 16 % 14 % (11 )% Expand


New York Post
2 hours ago
- New York Post
Severe outbreak of mosquito-borne chikungunya virus infects 8,000 in China
Thousands of people have been infected with a painful mosquito-borne virus in China, prompting a response not seen since COVID — including a plan to release even larger mosquitos and fish to eat the ones spreading the disease. The chikungunya virus has rapidly spread to about 8,000 patients in just four weeks, mainly across China's Guangdong province to the south, with the city of Foshan being hit the hardest, according to The New York Times. But Hong Kong's first case was confirmed Monday, and the increasingly worrisome situation is stoking fears of a potential pandemic that would require strict restrictions. 4 A sanitation worker spraying insecticide to precent the spread of the chikungunya virus in Dongguan, China on Aug. 3, 2025. Photo by VCG/VCG via Getty Images In a massive effort to curb further spread, masked Chinese soldiers have been dousing public spaces with insecticide, and authorities have begun releasing 'elephant mosquitoes' whose larvae devour the smaller, virus-carrying mosquitoes. Thousands of mosquito-eating fish also have been released into Foshan's public ponds. Chikungunya is not spread between humans but is transmitted by the bites of infected Aedes mosquitoes. While it's typically not deadly, there is no known cure, and the virus' symptoms can be agonizing and include fever, joint pain, headache, muscle pain, swelling and rash, according to the US Centers for Disease Control and Prevention. Officials in China said 95% of the patients hospitalized with the virus have been discharged within seven days, but the infection rate has the region on high alert with 3,000 cases reported in area in just the past week alone, according to the BBC. 4 Insecticide getting sprayed over a residential community in Dongguan on July 28, 2025. VCG via Getty Images The swift response by the Chinese government has its citizens online comparing the outbreak to the COVID-19 pandemic, which exploded in 2020 and killed millions of people. US officials claim the coronavirus was accidentally released from a Chinese laboratory. China imposed some of the strictest restrictions in the world at the time, including major lockdowns, forced testing and social-distancing rules. In Guangdong, authorities have vowed to take 'decisive and forceful measures' to halt the spread of chikungunya, which is not commonly found as far north as in China. 4 The chikungunya virus has spread to 8,000 patients in China in just four weeks. VCG via Getty Images Infected residents are being sent to 'quarantine wards' where they're placed in beds covered by mosquito nets. Officials have urged those showing any symptoms to be tested for the virus, and residents have been ordered to remove stagnant water, where the mosquitoes breed, from their homes — and threatened with fines up to $1,400 if they refuse to comply, according to the BBC. At least five homes have had their electricity cut for not cooperating, the Times reported. 4 A drone being used to spray insecticide in Guangzhou on Aug. 1, 2025. China News Service via Getty Images Ren Chao, a professor at the University of Hong Kong studying climate change's impact on Chikungunya, told the paper that infected mosquitos 'can spread and reproduce in even the smallest pool of water, like a Coke bottle cap.' The CDC on Friday issued a Level 2 travel notice for those going to China as the disease continues to spread. Level 2, which tells travelers to 'practice enhanced precautions,' is on a warning scale of four, with four urging people to 'avoid all travel' to the region. The agency has urged Americans traveling there to get vaccinated for chikungunya. There are two vaccines approved for use against it in the US. The current surge began in early 2025, with major outbreaks in the same Indian Ocean area. With Post Wires


San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
CDC issues travel warning as chikungunya outbreak grows in China
U.S. health officials have issued a travel advisory for parts of China following a surge in chikungunya infections, a mosquito-borne viral disease that has sickened more than 7,000 people in Guangdong province since mid-June. The Centers for Disease Control and Prevention is urging travelers to exercise 'increased caution,' particularly in the city of Foshan, the epicenter of the outbreak. Chikungunya, primarily transmitted by Aedes mosquitoes, causes fever and severe joint pain that can last for months or even years. While the disease is rarely fatal, it poses elevated risks for newborns, the elderly and individuals with underlying health conditions, according to the CDC. Globally, the virus has led to over 240,000 infections and 90 deaths so far in 2025, the European Centre for Disease Prevention and Control reported. In Foshan, authorities implemented hospital protocols r eminiscent of the COVID-19 pandemic. Infected patients are isolated under mosquito nets and released only after testing negative or completing a mandatory seven-day hospital stay. Officials say nearly 95% of cases have been mild, with most patients recovering within a week. Chinese authorities have responded swiftly to combat the outbreak. Measures include large-scale mosquito control campaigns, steep fines for households that fail to eliminate standing water and the release of mosquito-eating fish and so-called 'elephant mosquitoes,' a species that preys on chikungunya-carrying insects. Drones are also being deployed to detect hidden breeding grounds. The CDC advises travelers to protect themselves by using insect repellent, wearing long-sleeved clothing and staying in air-conditioned or screened-in accommodations. Two chikungunya vaccines have been approved for use in the United States, though one has been flagged for potential adverse effects in people over the age of 60.